Cost-effectiveness of omalizumab in patients with severe persistent allergic asthma
Article first published online: 15 JAN 2007
Volume 62, Issue 2, pages 149–153, February 2007
How to Cite
Brown, R., Turk, F., Dale, P. and Bousquet, J. (2007), Cost-effectiveness of omalizumab in patients with severe persistent allergic asthma. Allergy, 62: 149–153. doi: 10.1111/j.1398-9995.2006.01310.x
- Issue published online: 15 JAN 2007
- Article first published online: 15 JAN 2007
- Accepted for publication 8 December 2006
- economic burden;
Background: The health, economic and societal burden of asthma is considerable, and is greatest in patients with severe asthma, particularly when inadequately controlled. Real-life studies that assess the effectiveness of treatment are of particular interest.
Methods: We determined the incremental cost-effectiveness ratio (ICER) of adding omalizumab to standard therapy using data from the real-life 1-year randomized open-label study (ETOPA) and using Canada as a reference country. Only patients receiving high-dose ICS plus LABA were included in the analysis, reflecting the EU label for omalizumab. Costs and quality-adjusted life years (QALYs) gained were used to calculate the ICER for omalizumab (cost/QALY). Probabilistic sensitivity analysis was performed to determine the 95% confidence interval and one-sided sensitivity analyses were performed.
Results: The base case lifetime analysis of standard therapy vs standard therapy plus add-on omalizumab for the first 5 years, gave an ICER of €31 209. Probabilistic sensitivity analysis indicated that the 95% confidence interval around the ICER was €27 739–€40 840. The ICER range for one-way sensitivity analyses was €23 762 without discounting to €66 443 without inclusion of asthma-related mortality.
Conclusions: This study demonstrates that add-on omalizumab therapy is cost-effective in patients with severe persistent allergic asthma.